Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease

被引:45
|
作者
Ulrich, D [1 ]
Hrynyschyn, K
Pallua, N
机构
[1] Rhein Westfal TH Aachen, Univ Hosp, Dept Plast Surg & Hand Surg, Burn Ctr, Aachen, Germany
[2] Ev Elisabeth Hosp Trier, Dept Plast Surg & Hand Surg, Trier, Germany
关键词
D O I
10.1097/01.PRS.0000081462.40448.49
中图分类号
R61 [外科手术学];
学科分类号
摘要
Dupuytren's contracture is a fibroproliferative disorder characterized by progressive deposition of mature collagen fibers. In other fibrotic diseases affecting organs such as the liver, lung, heart, and skin, matrix metalloproteinases (MMPs) and their natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), play an important role. In this study, serum concentrations of MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined in 22 patients (five women and 17 men; average age, 67 +/- 11 years) with Dupuytren's disease using all enzyme-linked immunosorbent assay. Tissue samples were obtained for standard histological and immunohistochemical analyses. Sera and samples of palmar fascia from 20 patients (13 women and seven men; average age, 60 +/- 15 years) who had undergone hand surgery for carpal tunnel syndrome were used as the control group. Statistical analysis was performed using the Mann-Whitney test. Patients with Dupuytren's contracture presented with a TIMP-1 concentration of 437 +/- 160 ng/nA, a significantly higher TIMP-1 concentration than that seen in the control patients, who had a concentration of 321 +/- 70 ng/ml (p < 0.05). Patients with a proliferative active disease (n = 14) had a significantly higher TIMP-1 concentration (525 +/- 136 ng/ml) than patients (n = 8) with a contracture in the late involutional and residual phase (286 +/- 41 ng/ml; p < 0.05). There were no significant differences in the TIMP-2, MMP-1, MMP-2, and MMP-9 serum concentrations between patients with palmar fibromatosis and the control group. Patients with Dupuytren's disease had a significantly lower MMP-to-TIMP ratio (1.1 +/- 0.3; p < 0.05) than the control group (1.5 +/- 0.35). Patients with all active palmar fibromatosis presented a significantly (p < 0.05) reduced ratio (1 +/- 0.2) compared with those in later phases (1.4 +/- 0.3). TIMP-1 and TIMP-2 could be detected in tissue of patients with Dupuytren's contracture, with an accumulation in proliferative areas. MMPs could be detected locally in Dupuytren's tissue ill a few patients, with less positive staining than for TIMPs. In the control group, there was just little or no staining for TIMPs and MMPs. The data indicate that the physiological balance between MMPs and their natural inhibitors is disturbed in patients with a proliferative active Dupuytren's disease. The decrease in the systemic MMP-to-TIMP ratio call cause increased synthesis and deposition of collagen, leading to palmar fibromatosis.
引用
收藏
页码:1279 / 1286
页数:8
相关论文
共 50 条
  • [21] Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in malignant lymphoma
    Lee, AW
    Lee, AH
    Lee, KY
    Kang, CS
    Shim, SI
    Kim, BK
    MODERN PATHOLOGY, 2002, 15 (01) : 250A - 250A
  • [22] Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases
    Bode, W
    Maskos, K
    BIOLOGICAL CHEMISTRY, 2003, 384 (06) : 863 - 872
  • [23] Plasma Profiles of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Patients with Pulmonary Hypertension
    Jasti, Kishan
    Bhashyam, Siva
    Vido, Diane
    Machen, Laurie
    Melegari, Carrie
    Murali, Srinivas
    CIRCULATION, 2008, 118 (18) : S1073 - S1073
  • [24] Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in malignant lymphoma
    Lee, AW
    Lee, AH
    Lee, KY
    Kang, CS
    Shim, SI
    Kim, BK
    LABORATORY INVESTIGATION, 2002, 82 (01) : 250A - 250A
  • [25] Tissue inhibitors of matrix metalloproteinases in cancer
    Blavier, L
    Henriet, P
    Imren, S
    DeClerck, YA
    INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 : 108 - 119
  • [26] Concentrations of Matrix Metalloproteinases and their Tissue Inhibitors in the Cerebrospinal Fluid of Patients with Alzheimer's Disease
    Mroczko, Barbara
    Groblewska, Magdalena
    Zboch, Marzena
    Kulczynska, Agnieszka
    Koper, Olga M.
    Szmitkowski, Maciej
    Kornhuber, Johannes
    Lewczuk, Piotr
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 40 (02) : 351 - 357
  • [27] Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas
    Söderström, M
    Aro, HT
    Ahonen, M
    Johansson, N
    Aho, A
    Ekfors, T
    Böhling, T
    Kähäri, VM
    Vuorio, E
    APMIS, 2001, 109 (04) : 305 - 315
  • [28] Matrix metalloproteinases and their tissue inhibitors in endocrinology
    Salamonsen, LA
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1996, 7 (01): : 28 - 34
  • [29] Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
    Tanaka, Komei
    Essick, Eric E.
    Connors, Lawreen H.
    Seldin, David C.
    Sam, Flora
    CIRCULATION, 2011, 124 (21)
  • [30] Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes
    Bhalla, Vikas
    Georgiopoulou, Vasiliki V.
    Azeem, Ali A.
    Marti, Catherine N.
    Cole, Robert T.
    Laskar, Sonjoy R.
    De Staercke, Christine
    Hooper, W. Craig
    Smith, Andrew L.
    Kalogeropoulos, Andreas P.
    Butler, Javed
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 151 (02) : 237 - 239